This article is more than 5 years old. Information may no longer be current.
Vyzulta approval tops November Glaucoma news
Click Here to Manage Email Alerts
The most read glaucoma-related article on Healio.com/OSN last month was the FDA’s approval of Bausch + Lomb’s Vyzulta, a once-daily eye drop for lowering IOP.
News from the American Academy of Ophthalmology meeting in New Orleans and an Asian approval of Eye Tech Care’s glaucoma treatment rounded out the top five.
Here is the month’s most-viewed glaucoma content:
1. FDA gives nod to Bausch + Lomb’s once-daily glaucoma drops
Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. It is the first prostaglandin analog to have nitric oxide as one of its metabolites. Read more here.
2. Xen gel stent ‘transformative’ to glaucoma practice
At the American Academy of Ophthalmology meeting, Nathan Radcliffe, MD, of New York Eye and Ear, discussed his implementation of the Allergan Xen gel stent for treating patients with refractory glaucoma or those in need of a minimally invasive glaucoma procedure to lower IOP. Watch the video here.
3. MicroPulse technology allows safe treatment of glaucoma, retina
David Gossage, DO, shares pearls on how to use MicroPulse technology (Iridex) for glaucoma and retina treatments. Watch the video here.
4. Single bimatoprost implant controls IOP at 2 years in some patients
All doses and strengths of Allergan’s bimatoprost sustained release implant demonstrated efficacy in patients with open-angle glaucoma, E. Randy Craven, MD, said at the American Academy of Ophthalmology meeting. Read more here.
5. Eye Tech Care’s glaucoma treatment approved in China
EyeOP1 treats glaucoma with high-intensity focused ultrasound technology and is the first noninvasive medical device approved for glaucoma treatment in China. Read more here.